Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bayer U.S. Rx Headed By Foster During Transition; BI U.S. CEO-Elect Is Carroll

Executive Summary

Bayer diagnostics exec Colin Foster is overseeing U.S. pharmaceuticals while the company resolves its future participation in the Rx drug sector

You may also be interested in...

Bayer Sheds R&D Projects Ahead Of Joint Venture, Is Flexible On Control

Bayer is reducing the size of its R&D pipeline through product eliminations and outlicensing opportunities to maximize its influence over a future pharmaceutical partnership, Management Board Chairman Werner Wenning announced Nov. 12

BI/Pfizer’s Spiriva Shows Bronchodilator Effect, Not Dyspnea, Cmte. Says

Boehringer Ingelheim/Pfizer's Spiriva demonstrates a clinically meaningful bronchodilator effect when used to treat chronic COPD patients, FDA's Pulmonary-Allergy Drugs Advisory Committee unanimously agreed Sept. 6

Bayer Seeking Smaller Pharma Partner; Will Retain Majority Share In Deal

Bayer is in discussions with smaller specialty pharmaceutical companies over potential partnerships as it looks to build up its drug business




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts